|
|
Vaccine Detail
|
gp100-Pulsed Peripheral Blood Mononuclear Cell Vaccine |
| Vaccine Information |
- Vaccine Name: gp100-Pulsed Peripheral Blood Mononuclear Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007487
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: gp100
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: Peripheral blood lymphocytes (PBL) harvested from host blood and stimulated in vitro with tumor-specific gp 100 antigen. 'Pulsing' PBL with gp100, a tumor associated antigen (TAA) commonly expressed by melanoma cells, may increase melanoma-reactive cytotoxic lymphocytes (CTL) in the PBL cell population. Autologous gp100-pulsed PBL have been administered to melanoma patients in order to augment cytotoxic immune responses to melanoma. (NCIT_C2762).
|
| Host Response |
|
|
| References |
NCIT_C2762: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2762]
|
|
